Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 5, 2010, Pages 881-888

  Scatena, Caroline D ^a   Kumer, Jeffrey L ^a   Arbitrario, Jennifer P ^a   Howlett, Anthony R ^a   Hawtin, Rachael E ^a   Fox, Judith A ^a   Silverman, Jeffrey A ^a  

^a Sunesis Pharmaceuticals Inc   (United States)

Author keywords

AML; Anthracycline; Bone marrow ablation; Cytarabine; Topoisomerase II; Voreloxin

Indexed keywords

CYTARABINE; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG; VORELOXIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW APLASIA; CELL PROLIFERATION; CELL STRAIN HL 60; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; THROMBOCYTE COUNT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD PLATELETS; BONE MARROW CELLS; CELL PROLIFERATION; CYTARABINE; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTES; MICE; NAPHTHYRIDINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; THIAZOLES;

EID: 77956228014     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1234-z     Document Type: Article

References (33)

1. Advani RH, Hurwitz HI, Gordon MS, Ebbinghaus SW, Mendelson DS, Wakelee HA, Hoch U, Silverman JA, Havrilla NA, Berman CJ, Fox JA, Allen RS, DC A (2009) Phase 1 Experience with Voreloxin, a First in Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A report on two dosing schedules (Submitted)
2. DS Alberts NR Bachur JL Holtzman 1971 The pharmacokinetics of daunomycin in man Clin Pharmacol Ther 12 96 104 1:STN:280:DyaE3M7gtVyrsg%3D%3D 5541137
3. PJ Burke JE Karp WP Vaughan 1981 Chemotherapy of leukemia in mice, rats, and humans relating time of humoral stimulation, tumor growth, and clinical response J Natl Cancer Inst 67 529 538 1:CAS:528:DyaL3MXlvVWit7c%3D 6944525
4. G Capranico P De Isabella S Penco S Tinelli F Zunino 1989 Role of DNA breakage in cytotoxicity of doxorubicin, 9-deoxydoxorubicin, and 4-demethyl-6-deoxydoxorubicin in Murine Leukemia P388 cells Cancer Res 49 2022 2027 1:CAS:528:DyaL1MXls1KrtLY%3D 2702645
5. TC Chou 2006 Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol Rev 58 621 681 10.1124/pr.58.3.10 1:CAS:528:DC%2BD28XhtVOhtLfL 16968952
6. TC Chou P Talaly 1977 A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems J Biol Chem 252 6438 6442 1:CAS:528:DyaE2sXlsVOqsrY%3D 893418
7. G Del Poeta R Stasi G Aronica A Venditti M Cox A Bruno F Buccisano M Masi M Tribalto S Amadori G Papa 1996 Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia Blood 87 1997 2004 1:STN:280:DyaK283gt1GhtA%3D%3D 8634450
8. MJ Evanchik D Allen JC Yoburn JA Silverman U Hoch 2009 Metabolism of (+)-1, 4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2- thiazolyl)-1, 8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agent Drug Metab Dispos 37 594 601 10.1124/dmd.108.023432 1:CAS:528:DC%2BD1MXislamtLc%3D 19074528
9. Everds N (2004) Hematology of the Mouse. In: Hedrich H (ed) The Laboratory Mouse. Elsevier Academic Press, Amsterdam
10. TM Fliedner D Graessle C Paulsen K Reimers 2002 Structure and function of bone marrow hemopoiesis: mechanisms of response to ionizing radiation exposure Cancer Biother Radiopharm 17 405 426 10.1089/108497802760363204 1:STN:280:DC%2BD38njslGgtw%3D%3D 12396705
11. DG Gilliland JD Griffin 2002 The roles of FLT3 in hematopoiesis and leukemia Blood 100 1532 1542 10.1182/blood-2002-02-0492 1:CAS:528: DC%2BD38XmslyhsLc%3D 12176867
12. Hawtin RE, Stockett DE, Byl JA, McDowell RS, Tan N, Arkin MR, Wang W, Conroy A, Osheroff N, J.A. F (2009) Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II
13. Hirte H, McGuire W, Edwards R, Husain A, Hoskins P, Michels J, Matulonis U, Sexton C, Mahadocon K, Fox J, Michelson G (2009) A phase 2 trial of voreloxin in women with platinum-resistant ovarian cancer. In: Proceedings, American Society of Clinical Oncology (ASCO) annual meeting
14. U Hoch J Lynch Y Sato S Kashimoto F Kajikawa Y Furutani J Silverman 2009 Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models Cancer Chemother Pharmacol 64 53 65 10.1007/s00280-008-0850-3 1:CAS:528:DC%2BD1MXlt1Kjtrw%3D 18931998
15. RS Jaenke D Deprez-DeCampeneere A Trouet 1980 Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit Cancer Res 40 3530 3536 1:CAS:528:DyaL3cXmtFGnsbs%3D 6934026
16. DW Kufe PP Major EM Egan GP Beardsley 1980 Correlation of cytotoxicity with incorporation of ara-C into DNA J Biol Chem 255 8997 9000 1:CAS:528:DyaL3cXlsl2ntbc%3D 7410404
17. DW Kufe D Munroe D Herrick E Egan D Spriggs 1984 Effects of 1-beta-D-arabinofuranosylcytosine incorporation on eukaryotic DNA template function Mol Pharmacol 26 128 134 1:CAS:528:DyaL2cXlt1alur0%3D 6431261
18. Lancet J (2009) Phase Ib/II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in relapsed or refractory AML patients. In: Proceedings, American Society of Clinical Oncology (ASCO) annual meeting
19. T Lapidot A Dar O Kollet 2005 How do stem cells find their way home? Blood 106 1901 1910 10.1182/blood-2005-04-1417 1:CAS:528:DC%2BD2MXhtVWksLzJ 15890683
20. M Levis R Pham BD Smith D Small 2004 In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects Blood 104 1145 1150 10.1182/blood-2004-01-0388 1:CAS:528:DC%2BD2cXmslKgsb4%3D 15126317
21. AF List 1996 Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia Leukemia 10 937 942 1:STN:280: DyaK283ms1Cquw%3D%3D 8667648
22. A Matsukage K Ono A Ohashi T Takahashi C Nakayama M Saneyoshi 1978 Inhibitory effect of 1-beta-D-arabinofuranosylthymine 5'-triphosphate and 1-beta-D-arabinofuranosylcytosine 5'-triphosphate on DNA polymerases from murine cells and oncornavirus Cancer Res 38 3076 3079 1:CAS:528:DyaE1cXlvFejsr0%3D 79444
23. J Moore I Nivison-Smith K Goh D Ma K Bradstock J Szer S Durrant A Schwarer P Bardy R Herrmann A Dodds 2007 Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia Biol Blood Marrow Transplant 13 601 607 10.1016/j.bbmt.2007.01.073 17448920
24. D Nielsen C Maare T Skovsgaard 1996 Cellular resistance to anthracyclines Gen Pharmacol 27 251 255 1:CAS:528:DyaK28XisVKgtrc%3D 8919638
25. Ravandi F, Stuart R, Maris M, Stone R, Cripe R, Cooper M, Strickland S, Turturro F, Stock W, Mahadocon K, Fox J, Michelson G, Berman C (2009) A phase II study of voreloxin as single agent therapy for elderly patients (pts) with newly diagnosed acute myeloid leukemia (AML). American Society of Clinical Oncology (ASCO) Annual Meeting
26. CP Reynolds BJ Maurer 2005 Evaluating response to antineoplastic drug combinations in tissue culture models Methods Mol Med 110 173 183 1:CAS:528:DC%2BD2MXktF2jurY%3D 15901935
27. PA Speth PC Linssen JB Boezeman HM Wessels C Haanen 1987 Leukemic cell and plasma daunomycin concentrations after bolus injection and 72 h infusion Cancer Chemother Pharmacol 20 311 315 1:STN:280:DyaL1c%2FotVyjsA%3D%3D 3690804
28. Stone RM, O'Donnell MR, Sekeres MA (2004) Acute Myeloid Leukemia: ASH education Hematology: 98-117
29. MS Tallman DG Gilliland JM Rowe 2005 Drug therapy for acute myeloid leukemia Blood 106 1154 1163 10.1182/blood-2005-01-0178 1:CAS:528: DC%2BD2MXosVejsLg%3D 15870183
30. R Wong SA Giralt T Martin DR Couriel A Anagnostopoulos C Hosing BS Andersson P Cano M Shahjahan C Ippoliti EH Estey J McMannis JL Gajewski RE Champlin M de Lima 2003 Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years Blood 102 3052 3059 10.1182/blood-2003-03-0855 1:CAS:528:DC%2BD3sXotF2ms7g%3D 12842990
31. L Zhao MG Wientjes JL Au 2004 Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses Clin Cancer Res 10 7994 8004 10.1158/1078-0432.CCR-04-1087 1:CAS:528:DC%2BD2cXhtVCrs7rJ 15585635
32. J Zittoun J Marquet JC David 1991 Mechanism of inhibition of DNA ligase in Ara-C treated cells Leuk Res 15 157 164 10.1016/0145-2126(91)90097-D 1:CAS:528:DyaK3MXkt1Wktb8%3D 2016906
33. J Zittoun J Marquet JC David D Maniey R Zittoun 1989 A study of the mechanisms of cytotoxicity of Ara-C on three human leukemic cell lines Cancer Chemother Pharmacol 24 251 255 10.1007/BF00257628 1:CAS:528:DyaL1MXltVylsbY%3D 2752506